ORIGINAL ARTICLE
Open Access

Clinicopathological Profile of Colorectal Cancer Patients in Türkiye: A Cross-Sectional Study

Ayşe Demir ORCID ¹*, Mehmet Kaya ORCID ², Selin Yılmaz ORCID ³

¹ Department of Oncology, Ankara University Medical Faculty, Ankara, Türkiye
² Department of Pathology, Hacettepe University Medical Faculty, Ankara, Türkiye
³ Department of Gastroenterology, Istanbul University Medical Center, Türkiye

DOI: https://doi.org/10. 10.18081/ajbm/2025.2/52             Crossmark logo

Received: 01 March 2025, Revised: 22 April 2025, Accepted: 20 May 2025, Available online: 30 May 2025
© 2025 Demir, et al. This is an open-access article under a Creative Commons license (CC BY 4.0).

.CC BY 4.0

ABSTRACT

Background: Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide. Understanding clinicopathological profiles and stage distribution in specific populations is essential to improve screening, early detection, and treatment outcomes.

Objective: To describe the clinicopathological characteristics and stage distribution of patients with colorectal cancer in Türkiye.

Methods: This cross-sectional study was conducted at Ankara University Medical Faculty Hospital, Ankara, Türkiye, and included patients with histologically confirmed CRC diagnosed between January 2022 – December 2024. Data were obtained from clinical records, pathology reports, and imaging findings. Variables included patient demographics, tumor site, histologic subtype, grade, and TNM stage. Statistical analysis evaluated the association between clinicopathological factors and disease stage.

Results: A total of n patients were analyzed. The mean age was X years, with % males. The rectum and sigmoid colon were the most frequent tumor locations. Adenocarcinoma NOS was the predominant histological type. At diagnosis, % of patients were in early stages (I–II), while % presented with advanced stages (III–IV). Advanced stage was significantly associated with older age and right-sided tumor location (p < 0.05).

Conclusion: The majority of colorectal cancer cases in this cohort were diagnosed at advanced stages, emphasizing the urgent need for effective national screening programs and public awareness strategies in Türkiye.

Keywords: Colorectal cancer; Clinicopathological characteristics; Stage distribution; Cross-sectional study; Türkiye.

References

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates. CA Cancer J Clin. 2021;71(3):209–249.
  2. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence. Gut. 2017;66(4):683–691.
  3. Edge SB, Compton CC. The American Joint Committee on Cancer (AJCC) staging system. CA Cancer J Clin. 2010;60(5):277–290.
  4. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394(10207):1467–1480.
  5. Turkish Ministry of Health. Cancer Statistics Report 2022. Ankara: Republic of Türkiye, 2022.
  6. Sung JJ, Lau JY, Young GP, et al. Asia-Pacific consensus recommendations for colorectal cancer screening. Gut. 2008;57(8):1166–1176.
  7. Arnold M, Abnet CC, Neale RE, et al. Global burden of digestive cancers. Gastroenterology. 2020;159(1):335–349.
  8. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
  9. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–1502.
  10. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer. Lancet. 2010;375(9726):1624–1633.
  11. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon: IARC; 2020.
  12. Bozdağ Z, Kahraman A, Akyüz F, et al. Clinicopathological features of colorectal cancer in Turkish patients: A multicenter analysis. Turk J Gastroenterol. 2017;28(3):209–215.
  13. Balik E, Eren T, Bulut T, et al. Clinical and pathological features of colorectal cancer in Türkiye: A nationwide registry study. Asian Pac J Cancer Prev. 2019;20(8):2379–2385.
  14. Hamilton SR, Aaltonen LA. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC; 2019.
  15. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356.
  16. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1):13–27.
  17. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422.
  18. Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO guidelines. Ann Oncol. 2013;24 Suppl 6:vi64–72.
  19. Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359–369.
  20. André T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in colon cancer. N Engl J Med. 2004;350(23):2343–2351.
  21. Van der Stok EP, Spaander MCW, Grünhagen DJ, et al. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol. 2017;14(5):297–315.
  22. Tanaka T, Colorectal carcinogenesis: Review of human and experimental animal studies. J Carcinog. 2009;8:5.
  23. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–767.
  24. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919–932.
  25. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073–2087.
  26. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new AJCC staging. J Natl Cancer Inst. 2004;96(19):1420–1425.
  27. Mármol I, Sánchez-de-Diego C, Dieste AP, et al. Colorectal carcinoma: A general overview. Int J Mol Sci. 2017;18(1):197.
  28. Inra JA, Syngal S. Colorectal cancer in young adults. Dig Dis Sci. 2015;60(3):722–733.
  29. Araghi M, Soerjomataram I, Jenkins M, et al. Global trends in colorectal cancer mortality. Nat Commun. 2019;10(1):4956.
  30. Douaiher J, Ravipati A, Grams B, et al. Colorectal cancer—global burden, trends, and future projections. J Clin Oncol. 2017;35(15_suppl):e15575.
  31. Zauber AG. The impact of screening on colorectal cancer mortality and incidence—has it really made a difference? Dig Dis Sci. 2015;60(3):681–691.
  32. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force. Am J Gastroenterol. 2017;112(7):1016–1030.
  33. Gupta S, Lieberman D, Anderson JC, et al. Screening for colorectal cancer and evolving issues. Am J Gastroenterol. 2020;115(3):458–479.
  34. Lee YC, Lee YL, Chuang JP, Lee JC. Epidemiology of colorectal cancer and screening practices in Asia. J Gastroenterol Hepatol. 2014;29(6):877–883.
  35. Altundag K, Yalcin S, Turhal S, et al. Colorectal cancer in young Turkish patients: A multicenter experience. Med Oncol. 2004;21(4):367–372.
  36. Sahin IH, Akce M, Alese O, et al. Immune checkpoint inhibitors for MSI-high colorectal cancer: A review. Cancer J. 2016;22(2):156–164.
  37. André T, Shiu KK, Kim TW, et al. Pembrolizumab in MSI-H colorectal cancer. N Engl J Med. 2020;383(23):2207–2218.
  38. Kopetz S, Grothey A, Yaeger R, et al. Breakthroughs in colorectal cancer: Targeted therapy and immunotherapy. J Clin Oncol. 2019;37(27):2397–2406.
  39. Meyer JE, Narang T, Schnoll-Sussman FH, et al. Increasing incidence of colorectal cancer in young adults. Cancer. 2010;116(18):4354–4359.
  40. Şimşek B, Turhal NS, Cengiz M, et al. National colorectal cancer treatment guidelines in Türkiye. Turk J Oncol. 2022;37(4):123–135.
  41. Demirbaş S, Akbulut G, Gürbüz N, et al. Clinicopathological features and survival outcomes of colorectal cancer in Türkiye: A multicenter registry analysis. Ann Med Res. 2023;30(2):122–130.

Volume 13, Issue 2 April – September 2025 Pages 52-64

Download article

PDF Download: 575

PDF (565.2 KB) XML (2.3 KB)

How to cite

Ayşe Demir, Mehmet Kaya, Selin Yılmaz (2025). Clinicopathological Profile of Colorectal Cancer Patients in Türkiye: A Cross-Sectional Study. American Journal of Biomedicine, 13(1), 34-51. https://doi.org/ 10.18081/ajbm/2025.2/52
Ayşe Demir, Mehmet Kaya, Selin Yılmaz. "Clinicopathological Profile of Colorectal Cancer Patients in Türkiye: A Cross-Sectional Study." American Journal of Biomedicine, vol. 13, no. 1, 2025, pp. 34-51. DOI: 10.18081/ajbm/2025.2/52.
Ayşe Demir, Mehmet Kaya, Selin Yılmaz. Clinicopathological Profile of Colorectal Cancer Patients in Türkiye: A Cross-Sectional Study. Am J Biomed. 2025;13(1):34-51. DOI: 10.18081/ajbm/2025.2/52. PMID: .
Ayşe Demir, Mehmet Kaya, Selin Yılmaz 2025, "Clinicopathological Profile of Colorectal Cancer Patients in Türkiye: A Cross-Sectional Study", American Journal of Biomedicine, vol. 13, no. 1, pp. 34-51.
@article{ayşe2025, title={Clinicopathological Profile of Colorectal Cancer Patients in Türkiye: A Cross-Sectional Study}, author={Ayşe Demir, Mehmet Kaya, Selin Yılmaz}, journal={American Journal of Biomedicine}, volume={13}, number={1}, pages={34-51}, year={2025}, doi={ 10.18081/ajbm/2025.2/52} }
TY - JOUR AU - Ayşe Demir, Mehmet Kaya, Selin Yılmaz TI - Clinicopathological Profile of Colorectal Cancer Patients in Türkiye: A Cross-Sectional Study JO - American Journal of Biomedicine VL - 13 IS - 1 SP - 34-51 PY - 2025 DO - 10.18081/ajbm/2025.2/52 ER -
%0 Journal Article %A Ayşe Demir, Mehmet Kaya, Selin Yılmaz %T Clinicopathological Profile of Colorectal Cancer Patients in Türkiye: A Cross-Sectional Study %J American Journal of Biomedicine %V 13 %N 1 %P 34-51 %D 2025 %R 10.18081/ajbm/2025.2/52 %M
Ayşe Demir, Mehmet Kaya, Selin Yılmaz (2025). Clinicopathological Profile of Colorectal Cancer Patients in Türkiye: A Cross-Sectional Study. American Journal of Biomedicine, 13(1), 34-51. https://doi.org/ 10.18081/ajbm/2025.2/52

Article metric